- Cadence Pharmaceuticals (CADX -4.6%) slips after the USPTO issued preliminary decision yesterday rejecting certain claims for one of two licensed patents underlying its Ofirmev injection, now part of a legal fight with Exela Pharma.
- In response, CADX notes that it's very common for the USPTO to reject some or all of the claims of a patent in an initial office action, and this is not a final decision, but just one step in the reexamination process, which can take many years to complete.
- The company doesn't expect the decision to have an adverse impact on the pending litigation against Exela.
Cadence Pharmaceuticals slips on USPTO rejection of certain claims on Ofirmev
From other sites
at Zacks.com (Mon, 3:59PM)
at Zacks.com (Mon, 8:57AM)
at 4-traders.com (Mon, 7:01AM)
at Nasdaq.com (Apr 9, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs